Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

ADRs lost ~15% in the premarket on Tuesday after the Danish drugmaker lowered its full-year outlook, citing, among other ...

People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...

Congestion pricing turned six months old Saturday, and Gov. Kathy Hochul is boasting that the tolling program is reducing traffic in the city, among other benefits. The number of vehicles is down ...

(NewsNation) — A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% lower risk of dementia, among other health benefits. Dr.